Short-Term Subcutaneous Allergy Immunotherapy and Dupilumab are Well Tolerated in Allergic Rhinitis: A Randomized Trial
Subcutaneous immunotherapy (SCIT) has been proven as an effective therapy against some allergens for seasonal allergic rhinitis (SAR) patients unresponsive to intranasal corticosteroids and/or antihistamines but carries risk of systemic allergic reactions. Dupilumab blocks the shared receptor compon...
Saved in:
| Published in | Journal of asthma and allergy Vol. 14; pp. 1045 - 1063 |
|---|---|
| Main Authors | , , , , , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
New Zealand
Dove Medical Press Limited
01.01.2021
Taylor & Francis Ltd Dove Dove Medical Press |
| Subjects | |
| Online Access | Get full text |
| ISSN | 1178-6965 1178-6965 |
| DOI | 10.2147/JAA.S318892 |
Cover
| Abstract | Subcutaneous immunotherapy (SCIT) has been proven as an effective therapy against some allergens for seasonal allergic rhinitis (SAR) patients unresponsive to intranasal corticosteroids and/or antihistamines but carries risk of systemic allergic reactions. Dupilumab blocks the shared receptor component for interleukin-4 and interleukin-13, key and central drivers of type 2 inflammation in multiple diseases.
To evaluate the efficacy and safety of SCIT+dupilumab vs SCIT alone.
This phase 2a, multicenter, double-blind, placebo-controlled parallel-group study conducted in 103 adults with grass pollen-induced SAR (NCT03558997) randomized patients 1:1:1:1 to SCIT, dupilumab (300 mg every 2 weeks), SCIT+dupilumab, or placebo. SCIT was administered using an 8-week cluster protocol followed by 8 weeks of maintenance injections. Primary endpoint was change from pre-treatment baseline in area under the curve (AUC) in total nasal symptom score (TNSS) 0-1 h following nasal allergen challenge (NAC) with timothy grass extract at Week 17.
Although 16 weeks of treatment with SCIT+dupilumab did not significantly improve TNSS AUC (0-1 h) following NAC at Week 17 vs SCIT (least squares mean -56.76% vs -52.03%), a higher proportion of SCIT+dupilumab-treated patients (61.5%) achieved SCIT maintenance dose vs SCIT (46.2%). A lower proportion of SCIT+dupilumab-treated patients (7.7%) required epinephrine rescue treatment vs SCIT (19.2%). There were significantly fewer withdrawals in the SCIT+dupilumab group than in the SCIT group (n = 2 [7.7%] vs n = 8 [30.8%];
= 0.0216); the majority of SCIT group withdrawals were due to SCIT-related intolerability, compared with no discontinuations from the SCIT+dupilumab group.
In SAR patients, 16 weeks of SCIT+dupilumab may improve SCIT tolerability but did not incrementally reduce post-allergen challenge nasal symptoms compared with SCIT alone.
NCT03558997. |
|---|---|
| AbstractList | Subcutaneous immunotherapy (SCIT) has been proven as an effective therapy against some allergens for seasonal allergic rhinitis (SAR) patients unresponsive to intranasal corticosteroids and/or antihistamines but carries risk of systemic allergic reactions. Dupilumab blocks the shared receptor component for interleukin-4 and interleukin-13, key and central drivers of type 2 inflammation in multiple diseases.BACKGROUNDSubcutaneous immunotherapy (SCIT) has been proven as an effective therapy against some allergens for seasonal allergic rhinitis (SAR) patients unresponsive to intranasal corticosteroids and/or antihistamines but carries risk of systemic allergic reactions. Dupilumab blocks the shared receptor component for interleukin-4 and interleukin-13, key and central drivers of type 2 inflammation in multiple diseases.To evaluate the efficacy and safety of SCIT+dupilumab vs SCIT alone.OBJECTIVETo evaluate the efficacy and safety of SCIT+dupilumab vs SCIT alone.This phase 2a, multicenter, double-blind, placebo-controlled parallel-group study conducted in 103 adults with grass pollen-induced SAR (NCT03558997) randomized patients 1:1:1:1 to SCIT, dupilumab (300 mg every 2 weeks), SCIT+dupilumab, or placebo. SCIT was administered using an 8-week cluster protocol followed by 8 weeks of maintenance injections. Primary endpoint was change from pre-treatment baseline in area under the curve (AUC) in total nasal symptom score (TNSS) 0-1 h following nasal allergen challenge (NAC) with timothy grass extract at Week 17.METHODSThis phase 2a, multicenter, double-blind, placebo-controlled parallel-group study conducted in 103 adults with grass pollen-induced SAR (NCT03558997) randomized patients 1:1:1:1 to SCIT, dupilumab (300 mg every 2 weeks), SCIT+dupilumab, or placebo. SCIT was administered using an 8-week cluster protocol followed by 8 weeks of maintenance injections. Primary endpoint was change from pre-treatment baseline in area under the curve (AUC) in total nasal symptom score (TNSS) 0-1 h following nasal allergen challenge (NAC) with timothy grass extract at Week 17.Although 16 weeks of treatment with SCIT+dupilumab did not significantly improve TNSS AUC (0-1 h) following NAC at Week 17 vs SCIT (least squares mean -56.76% vs -52.03%), a higher proportion of SCIT+dupilumab-treated patients (61.5%) achieved SCIT maintenance dose vs SCIT (46.2%). A lower proportion of SCIT+dupilumab-treated patients (7.7%) required epinephrine rescue treatment vs SCIT (19.2%). There were significantly fewer withdrawals in the SCIT+dupilumab group than in the SCIT group (n = 2 [7.7%] vs n = 8 [30.8%]; P = 0.0216); the majority of SCIT group withdrawals were due to SCIT-related intolerability, compared with no discontinuations from the SCIT+dupilumab group.RESULTSAlthough 16 weeks of treatment with SCIT+dupilumab did not significantly improve TNSS AUC (0-1 h) following NAC at Week 17 vs SCIT (least squares mean -56.76% vs -52.03%), a higher proportion of SCIT+dupilumab-treated patients (61.5%) achieved SCIT maintenance dose vs SCIT (46.2%). A lower proportion of SCIT+dupilumab-treated patients (7.7%) required epinephrine rescue treatment vs SCIT (19.2%). There were significantly fewer withdrawals in the SCIT+dupilumab group than in the SCIT group (n = 2 [7.7%] vs n = 8 [30.8%]; P = 0.0216); the majority of SCIT group withdrawals were due to SCIT-related intolerability, compared with no discontinuations from the SCIT+dupilumab group.In SAR patients, 16 weeks of SCIT+dupilumab may improve SCIT tolerability but did not incrementally reduce post-allergen challenge nasal symptoms compared with SCIT alone.CONCLUSIONIn SAR patients, 16 weeks of SCIT+dupilumab may improve SCIT tolerability but did not incrementally reduce post-allergen challenge nasal symptoms compared with SCIT alone.NCT03558997.CLINICAL STUDY NUMBERNCT03558997. Background: Subcutaneous immunotherapy (SCIT) has been proven as an effective therapy against some allergens for seasonal allergic rhinitis (SAR) patients unresponsive to intranasal corticosteroids and/or antihistamines but carries risk of systemic allergic reactions. Dupilumab blocks the shared receptor component for interleukin-4 and interleukin-13, key and central drivers of type 2 inflammation in multiple diseases. Objective: To evaluate the efficacy and safety of SCIT+dupilumab vs SCIT alone. Methods: This phase 2a, multicenter, double-blind, placebo-controlled parallel-group study conducted in 103 adults with grass pollen-induced SAR (NCT03558997) randomized patients 1:1:1:1 to SCIT, dupilumab (300 mg every 2 weeks), SCIT+dupilumab, or placebo. SCIT was administered using an 8-week cluster protocol followed by 8 weeks of maintenance injections. Primary endpoint was change from pre-treatment baseline in area under the curve (AUC) in total nasal symptom score (TNSS) 0-1 h following nasal allergen challenge (NAC) with timothy grass extract at Week 17. Results: Although 16 weeks of treatment with SCIT+dupilumab did not significantly improve TNSS AUC (0-1 h) following NAC at Week 17 vs SCIT (least squares mean -56.76% vs -52.03%), a higher proportion of SCIT+dupilumab-treated patients (61.5%) achieved SCIT maintenance dose vs SCIT (46.2%). A lower proportion of SCIT+dupilumab-treated patients (7.7%) required epinephrine rescue treatment vs SCIT (19.2%). There were significantly fewer withdrawals in the SCIT+dupilumab group than in the SCIT group (n = 2 [7.7%] vs n = 8 [30.8%]; P = 0.0216); the majority of SCIT group withdrawals were due to SCIT-related intolerability, compared with no discontinuations from the SCIT+dupilumab group. Conclusion: In SAR patients, 16 weeks of SCIT+dupilumab may improve SCIT tolerability but did not incrementally reduce post-allergen challenge nasal symptoms compared with SCIT alone. Clinical Study Number: NCT03558997 Keywords: dupilumab, seasonal allergic rhinitis, subcutaneous immunotherapy, nasal allergen responses Background: Subcutaneous immunotherapy (SCIT) has been proven as an effective therapy against some allergens for seasonal allergic rhinitis (SAR) patients unresponsive to intranasal corticosteroids and/or antihistamines but carries risk of systemic allergic reactions. Dupilumab blocks the shared receptor component for interleukin-4 and interleukin-13, key and central drivers of type 2 inflammation in multiple diseases. Objective: To evaluate the efficacy and safety of SCIT+dupilumab vs SCIT alone. Methods: This phase 2a, multicenter, double-blind, placebo-controlled parallel-group study conducted in 103 adults with grass pollen-induced SAR (NCT03558997) randomized patients 1:1:1:1 to SCIT, dupilumab (300 mg every 2 weeks), SCIT+dupilumab, or placebo. SCIT was administered using an 8-week cluster protocol followed by 8 weeks of maintenance injections. Primary endpoint was change from pre-treatment baseline in area under the curve (AUC) in total nasal symptom score (TNSS) 0– 1 h following nasal allergen challenge (NAC) with timothy grass extract at Week 17. Results: Although 16 weeks of treatment with SCIT+dupilumab did not significantly improve TNSS AUC (0– 1 h) following NAC at Week 17 vs SCIT (least squares mean − 56.76% vs − 52.03%), a higher proportion of SCIT+dupilumab-treated patients (61.5%) achieved SCIT maintenance dose vs SCIT (46.2%). A lower proportion of SCIT+dupilumab-treated patients (7.7%) required epinephrine rescue treatment vs SCIT (19.2%). There were significantly fewer withdrawals in the SCIT+dupilumab group than in the SCIT group (n = 2 [7.7%] vs n = 8 [30.8%]; P = 0.0216); the majority of SCIT group withdrawals were due to SCIT-related intolerability, compared with no discontinuations from the SCIT+dupilumab group. Conclusion: In SAR patients, 16 weeks of SCIT+dupilumab may improve SCIT tolerability but did not incrementally reduce post-allergen challenge nasal symptoms compared with SCIT alone. Clinical Study Number: NCT03558997. Jonathan Corren,1 Sarbjit S Saini,2 Remi Gagnon,3 Mark H Moss,4 Gordon Sussman,5 Joshua Jacobs,6 Elizabeth Laws,7 Elinore S Chung,8 Tatiana Constant,8 Yiping Sun,8 Jennifer Maloney,8 Jennifer D Hamilton,8 Marcella Ruddy,8 Claire Q Wang,8 Meagan P O’Brien8 1Departments of Medicine and Pediatrics, David Geffen School of Medicine, University of California, Los Angeles, CA, USA; 2Department of Internal Medicine, Division of Allergy and Clinical Immunology, Johns Hopkins Asthma and Allergy Center, Baltimore, MD, USA; 3Clinique Spécialisée en Allergie de la Capitale, Québec, QC, Canada; 4Departments of Medicine and Pediatrics, Division of Allergy, Pulmonary and Critical Care, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA; 5Department of Medicine, University of Toronto, Toronto, ON, Canada; 6Allergy and Asthma Clinical Research, Inc, Walnut Creek, CA, USA; 7Sanofi, Bridgewater, NJ, USA; 8Regeneron Pharmaceuticals, Inc, Tarrytown, NY, USACorrespondence: Meagan P O’BrienRegeneron Pharmaceuticals, Inc, 777 Old Saw Mill River Road, Tarrytown, NY, 10591, USATel +1 914 826-5271Email meagan.obrien@regeneron.comJonathan CorrenDepartments of Medicine and Pediatrics, David Geffen School of Medicine, University of California, Los Angeles, 10833 Le Conte Ave, Los Angeles, CA, 90095, USATel +1 310 312-5050, ext 250Email jcorren@ucla.eduBackground: Subcutaneous immunotherapy (SCIT) has been proven as an effective therapy against some allergens for seasonal allergic rhinitis (SAR) patients unresponsive to intranasal corticosteroids and/or antihistamines but carries risk of systemic allergic reactions. Dupilumab blocks the shared receptor component for interleukin-4 and interleukin-13, key and central drivers of type 2 inflammation in multiple diseases.Objective: To evaluate the efficacy and safety of SCIT+dupilumab vs SCIT alone.Methods: This phase 2a, multicenter, double-blind, placebo-controlled parallel-group study conducted in 103 adults with grass pollen-induced SAR (NCT03558997) randomized patients 1:1:1:1 to SCIT, dupilumab (300 mg every 2 weeks), SCIT+dupilumab, or placebo. SCIT was administered using an 8-week cluster protocol followed by 8 weeks of maintenance injections. Primary endpoint was change from pre-treatment baseline in area under the curve (AUC) in total nasal symptom score (TNSS) 0– 1 h following nasal allergen challenge (NAC) with timothy grass extract at Week 17.Results: Although 16 weeks of treatment with SCIT+dupilumab did not significantly improve TNSS AUC (0– 1 h) following NAC at Week 17 vs SCIT (least squares mean − 56.76% vs − 52.03%), a higher proportion of SCIT+dupilumab-treated patients (61.5%) achieved SCIT maintenance dose vs SCIT (46.2%). A lower proportion of SCIT+dupilumab-treated patients (7.7%) required epinephrine rescue treatment vs SCIT (19.2%). There were significantly fewer withdrawals in the SCIT+dupilumab group than in the SCIT group (n = 2 [7.7%] vs n = 8 [30.8%]; P = 0.0216); the majority of SCIT group withdrawals were due to SCIT-related intolerability, compared with no discontinuations from the SCIT+dupilumab group.Conclusion: In SAR patients, 16 weeks of SCIT+dupilumab may improve SCIT tolerability but did not incrementally reduce post-allergen challenge nasal symptoms compared with SCIT alone.Clinical Study Number: NCT03558997.Keywords: dupilumab, seasonal allergic rhinitis, subcutaneous immunotherapy, nasal allergen responses Clinical Study Number: NCT03558997 Subcutaneous immunotherapy (SCIT) has been proven as an effective therapy against some allergens for seasonal allergic rhinitis (SAR) patients unresponsive to intranasal corticosteroids and/or antihistamines but carries risk of systemic allergic reactions. Dupilumab blocks the shared receptor component for interleukin-4 and interleukin-13, key and central drivers of type 2 inflammation in multiple diseases. To evaluate the efficacy and safety of SCIT+dupilumab vs SCIT alone. This phase 2a, multicenter, double-blind, placebo-controlled parallel-group study conducted in 103 adults with grass pollen-induced SAR (NCT03558997) randomized patients 1:1:1:1 to SCIT, dupilumab (300 mg every 2 weeks), SCIT+dupilumab, or placebo. SCIT was administered using an 8-week cluster protocol followed by 8 weeks of maintenance injections. Primary endpoint was change from pre-treatment baseline in area under the curve (AUC) in total nasal symptom score (TNSS) 0-1 h following nasal allergen challenge (NAC) with timothy grass extract at Week 17. Although 16 weeks of treatment with SCIT+dupilumab did not significantly improve TNSS AUC (0-1 h) following NAC at Week 17 vs SCIT (least squares mean -56.76% vs -52.03%), a higher proportion of SCIT+dupilumab-treated patients (61.5%) achieved SCIT maintenance dose vs SCIT (46.2%). A lower proportion of SCIT+dupilumab-treated patients (7.7%) required epinephrine rescue treatment vs SCIT (19.2%). There were significantly fewer withdrawals in the SCIT+dupilumab group than in the SCIT group (n = 2 [7.7%] vs n = 8 [30.8%]; = 0.0216); the majority of SCIT group withdrawals were due to SCIT-related intolerability, compared with no discontinuations from the SCIT+dupilumab group. In SAR patients, 16 weeks of SCIT+dupilumab may improve SCIT tolerability but did not incrementally reduce post-allergen challenge nasal symptoms compared with SCIT alone. NCT03558997. |
| Audience | Academic |
| Author | Corren, Jonathan Jacobs, Joshua Maloney, Jennifer Laws, Elizabeth Moss, Mark H Ruddy, Marcella Gagnon, Remi Hamilton, Jennifer D Wang, Claire Q Saini, Sarbjit S Sun, Yiping O’Brien, Meagan P Chung, Elinore S Constant, Tatiana Sussman, Gordon |
| Author_xml | – sequence: 1 givenname: Jonathan surname: Corren fullname: Corren, Jonathan – sequence: 2 givenname: Sarbjit S orcidid: 0000-0001-8522-2742 surname: Saini fullname: Saini, Sarbjit S – sequence: 3 givenname: Remi surname: Gagnon fullname: Gagnon, Remi – sequence: 4 givenname: Mark H surname: Moss fullname: Moss, Mark H – sequence: 5 givenname: Gordon surname: Sussman fullname: Sussman, Gordon – sequence: 6 givenname: Joshua surname: Jacobs fullname: Jacobs, Joshua – sequence: 7 givenname: Elizabeth surname: Laws fullname: Laws, Elizabeth – sequence: 8 givenname: Elinore S surname: Chung fullname: Chung, Elinore S – sequence: 9 givenname: Tatiana orcidid: 0000-0001-8619-8131 surname: Constant fullname: Constant, Tatiana – sequence: 10 givenname: Yiping surname: Sun fullname: Sun, Yiping – sequence: 11 givenname: Jennifer surname: Maloney fullname: Maloney, Jennifer – sequence: 12 givenname: Jennifer D surname: Hamilton fullname: Hamilton, Jennifer D – sequence: 13 givenname: Marcella surname: Ruddy fullname: Ruddy, Marcella – sequence: 14 givenname: Claire Q surname: Wang fullname: Wang, Claire Q – sequence: 15 givenname: Meagan P surname: O’Brien fullname: O’Brien, Meagan P |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/34429614$$D View this record in MEDLINE/PubMed |
| BookMark | eNptkl2L1DAUhousuOu6V95LQRBBZmya5msvhLJ-jSwIOyNehrQ9nWZJkzFNlfHXmzqzOrNse9GQPu_T5uU8TU6ss5Akz1E2z1HB3n4py_kSI85F_ig5Q4jxGRWUnBysT5OLYbjN4oUFpZg-SU5xUeSCouIs-bXsnA-zFfg-XY5VPQZlwY1DWhoDfr1NF30_Whc68GqzTZVt0vfjRpuxV1WqPKTfwZh05SKsAjSptvukrtObTlsd9HCZlulNTLpe_47IymtlniWPW2UGuNg_z5NvHz-srj7Prr9-WlyV17OaMBxmiLYEGl4JEFWmSMaYahCtoAXWCEWKllMCbUMwwXnFc4CcKhJP2VDespwjfJ4sdt7GqVu58bpXfiud0vLvhvNrqXzQtQGpkMgVIwUDmhWijmooCGZVxWhDMppF17udazNWPTQ12OCVOZIev7G6k2v3U3LMBEOT4PVe4N2PEYYgez3UscBd5zIntCg4w0hE9OU99NaN3saqJgoxzAUq_lNrFQ-gbevid-tJKkvKCGe54BM1f4CKdwO9ruM8tTruHwVeHQQ6UCZ0gzNj0M4Ox-CLw0b-VXE3XxFAO6D2bhg8tLLWQU2e-AvaSJTJaYxlHGO5H-OYeXMvc6d9iP4Dz4Pwaw |
| CitedBy_id | crossref_primary_10_3390_jcm12082848 crossref_primary_10_1002_alr_23090 crossref_primary_10_1016_j_intimp_2023_111137 crossref_primary_10_1111_all_16001 crossref_primary_10_1111_all_16089 crossref_primary_10_1002_jcph_2004 crossref_primary_10_1080_14656566_2024_2336082 crossref_primary_10_1111_all_15653 crossref_primary_10_1016_j_anai_2024_06_016 crossref_primary_10_1016_j_eclinm_2024_102467 crossref_primary_10_1111_all_15454 crossref_primary_10_1080_08998280_2024_2395213 crossref_primary_10_1111_all_15799 crossref_primary_10_5415_apallergy_0000000000000174 crossref_primary_10_1016_j_rmr_2024_08_004 crossref_primary_10_2174_2772270817666230320153734 crossref_primary_10_3390_nu16162797 crossref_primary_10_1097_MOO_0000000000000865 crossref_primary_10_1016_j_waojou_2024_100968 crossref_primary_10_1007_s40521_024_00377_6 crossref_primary_10_1002_eji_202249983 crossref_primary_10_3390_ph17111510 crossref_primary_10_3390_jcm11206062 crossref_primary_10_1016_j_jaci_2024_01_028 crossref_primary_10_3389_falgy_2022_1019255 crossref_primary_10_1080_17476348_2023_2251403 crossref_primary_10_3390_biomedicines10112874 crossref_primary_10_1016_j_jaip_2023_08_047 crossref_primary_10_1038_s41577_022_00786_1 crossref_primary_10_1016_j_heliyon_2024_e32756 crossref_primary_10_1111_all_15945 crossref_primary_10_1016_j_bjorl_2024_101500 crossref_primary_10_1016_j_waojou_2025_101043 crossref_primary_10_1097_ACI_0000000000000853 crossref_primary_10_4168_aair_2024_16_6_682 crossref_primary_10_1002_eer3_5 crossref_primary_10_1080_02770903_2024_2391441 crossref_primary_10_2174_0113816128295952240306072100 crossref_primary_10_1016_j_otc_2023_08_008 crossref_primary_10_1016_j_jaci_2023_07_009 crossref_primary_10_1007_s13555_024_01231_y |
| Cites_doi | 10.1016/j.jaad.2020.06.054 10.1016/j.jaci.2017.11.051 10.1016/j.iac.2019.09.001 10.1126/scitranslmed.aam9171 10.1016/j.jaip.2016.08.017 10.1111/cea.13775 10.1080/1744666X.2017.1298443 10.1016/j.anai.2011.06.026 10.1111/bjd.16156 10.1016/j.jaci.2009.10.060 10.1111/all.14338 10.1007/s40521-018-0176-2 10.1016/j.jaci.2015.08.046 10.1126/science.aau2599 10.1016/S0140-6736(19)31881-1 10.1111/all.13208 10.1016/j.jaip.2019.01.058 10.1016/j.amjoto.2019.07.013 10.1111/all.14151 10.1056/NEJM199908123410702 10.1111/j.1365-2222.2006.02340 10.4049/jimmunol.179.12.8180 10.4049/jimmunol.145.11.3796 10.1001/jama.2016.21040 10.1016/j.jaci.2005.10.010 10.1016/j.anai.2020.05.026 10.1016/j.jaci.2010.09.034 10.1016/S0140-6736(17)31191-1 10.1016/j.jaci.2015.12.1298 10.1159/000513158 10.1016/0091-6749(82)90062-8 10.1056/NEJMoa1610020 10.1111/jdv.16928 10.1111/all.13685 10.1016/j.jaip.2014.01.004 10.1111/all.13262 10.1084/jem.168.3.853 10.1111/j.1398-9995.2011.02745.x 10.1177/0194599814561600 10.1016/j.alit.2020.08.002 10.1111/j.1398-9995.2004.00550.x 10.1016/j.imlet.2020.08.002 10.4049/jimmunol.160.7.3555 10.1056/NEJMoa1804092 |
| ContentType | Journal Article |
| Copyright | 2021 Corren et al. COPYRIGHT 2021 Dove Medical Press Limited 2021. This work is licensed under https://creativecommons.org/licenses/by-nc/3.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. 2021 Corren et al. 2021 Corren et al. |
| Copyright_xml | – notice: 2021 Corren et al. – notice: COPYRIGHT 2021 Dove Medical Press Limited – notice: 2021. This work is licensed under https://creativecommons.org/licenses/by-nc/3.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: 2021 Corren et al. 2021 Corren et al. |
| DBID | AAYXX CITATION NPM 3V. 7RV 7XB 8C1 8FE 8FH 8FI 8FJ 8FK 8G5 ABUWG AFKRA AZQEC BBNVY BENPR BHPHI CCPQU DWQXO FYUFA GHDGH GNUQQ GUQSH HCIFZ KB0 LK8 M2O M7P MBDVC NAPCQ PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQGLB PQQKQ PQUKI PRINS Q9U 7X8 5PM DOA |
| DOI | 10.2147/JAA.S318892 |
| DatabaseName | CrossRef PubMed ProQuest Central (Corporate) Nursing & Allied Health Database ProQuest Central (purchase pre-March 2016) Public Health Database ProQuest SciTech Collection ProQuest Natural Science Journals ProQuest Hospital Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Research Library ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials Biological Science Collection ProQuest Central Natural Science Collection ProQuest One ProQuest Central Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student ProQuest Research Library SciTech Premium Collection Nursing & Allied Health Database (Alumni Edition) Biological Sciences Research Library Biological Science Database Research Library (Corporate) Nursing & Allied Health Premium ProQuest Central Premium ProQuest One Academic (New) Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Applied & Life Sciences ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China ProQuest Central Basic MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef PubMed Publicly Available Content Database Research Library Prep ProQuest Central Student ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Central (Alumni Edition) SciTech Premium Collection ProQuest One Community College ProQuest One Health & Nursing Research Library (Alumni Edition) ProQuest Natural Science Collection ProQuest Central China ProQuest Central ProQuest One Applied & Life Sciences ProQuest Health & Medical Research Collection Health Research Premium Collection Natural Science Collection ProQuest Central Korea Health & Medical Research Collection Biological Science Collection ProQuest Research Library ProQuest Central (New) ProQuest Public Health ProQuest Biological Science Collection ProQuest Central Basic ProQuest One Academic Eastern Edition ProQuest Nursing & Allied Health Source ProQuest Hospital Collection Health Research Premium Collection (Alumni) Biological Science Database ProQuest SciTech Collection ProQuest Hospital Collection (Alumni) Nursing & Allied Health Premium ProQuest One Academic UKI Edition ProQuest Nursing & Allied Health Source (Alumni) ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic Publicly Available Content Database PubMed |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: BENPR name: ProQuest Central url: http://www.proquest.com/pqcentral?accountid=15518 sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| DocumentTitleAlternate | Corren et al |
| EISSN | 1178-6965 |
| EndPage | 1063 |
| ExternalDocumentID | oai_doaj_org_article_a192a7547e6049cf86e4537bb76d5060 PMC8379710 A675872984 34429614 10_2147_JAA_S318892 |
| Genre | Journal Article |
| GeographicLocations | France Canada United Kingdom |
| GeographicLocations_xml | – name: United Kingdom – name: Canada – name: France |
| GrantInformation_xml | – fundername: ; |
| GroupedDBID | --- 0YH 29J 2WC 5VS 7RV 8C1 8FE 8FH 8FI 8FJ 8G5 AAYXX ABUWG ACGFO ADBBV ADRAZ AFKRA ALMA_UNASSIGNED_HOLDINGS AOIJS AZQEC BAWUL BBNVY BCNDV BENPR BHPHI BKEYQ BPHCQ BVXVI CCPQU CITATION DIK DWQXO E3Z EBD EBS EJD FYUFA GNUQQ GROUPED_DOAJ GUQSH GX1 HCIFZ HYE IAO IHR IHW IPNFZ ITC KQ8 LK8 M2O M48 M7P M~E NAPCQ O5R O5S OK1 P2P P6G PGMZT PHGZM PHGZT PIMPY PJZUB PPXIY PQGLB PQQKQ PROAC PUEGO RIG RNS RPM TDBHL TR2 UKHRP VDV ALIPV NPM PMFND 3V. 7XB 8FK MBDVC PKEHL PQEST PQUKI PRINS Q9U 7X8 5PM |
| ID | FETCH-LOGICAL-c573t-16f5ed8b9e9b0a5077ad16befe7d9a54f865efd53532b82ee26a5966d68f72813 |
| IEDL.DBID | M48 |
| ISSN | 1178-6965 |
| IngestDate | Wed Aug 27 01:14:56 EDT 2025 Tue Sep 30 16:57:27 EDT 2025 Thu Sep 04 16:13:15 EDT 2025 Fri Jul 25 09:59:06 EDT 2025 Tue Jun 17 21:30:12 EDT 2025 Tue Jun 10 20:28:56 EDT 2025 Thu May 22 21:21:30 EDT 2025 Thu Jan 02 22:55:22 EST 2025 Thu Apr 24 22:56:14 EDT 2025 Wed Oct 01 04:12:18 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Keywords | nasal allergen responses seasonal allergic rhinitis subcutaneous immunotherapy dupilumab |
| Language | English |
| License | http://creativecommons.org/licenses/by-nc/3.0 2021 Corren et al. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c573t-16f5ed8b9e9b0a5077ad16befe7d9a54f865efd53532b82ee26a5966d68f72813 |
| Notes | ObjectType-Article-1 ObjectType-Evidence Based Healthcare-3 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
| ORCID | 0000-0001-8522-2742 0000-0001-8619-8131 |
| OpenAccessLink | http://journals.scholarsportal.info/openUrl.xqy?doi=10.2147/JAA.S318892 |
| PMID | 34429614 |
| PQID | 2561738914 |
| PQPubID | 3933137 |
| PageCount | 19 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_a192a7547e6049cf86e4537bb76d5060 pubmedcentral_primary_oai_pubmedcentral_nih_gov_8379710 proquest_miscellaneous_2564487319 proquest_journals_2561738914 gale_infotracmisc_A675872984 gale_infotracacademiconefile_A675872984 gale_healthsolutions_A675872984 pubmed_primary_34429614 crossref_citationtrail_10_2147_JAA_S318892 crossref_primary_10_2147_JAA_S318892 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2021-01-01 |
| PublicationDateYYYYMMDD | 2021-01-01 |
| PublicationDate_xml | – month: 01 year: 2021 text: 2021-01-01 day: 01 |
| PublicationDecade | 2020 |
| PublicationPlace | New Zealand |
| PublicationPlace_xml | – name: New Zealand – name: Macclesfield |
| PublicationTitle | Journal of asthma and allergy |
| PublicationTitleAlternate | J Asthma Allergy |
| PublicationYear | 2021 |
| Publisher | Dove Medical Press Limited Taylor & Francis Ltd Dove Dove Medical Press |
| Publisher_xml | – name: Dove Medical Press Limited – name: Taylor & Francis Ltd – name: Dove – name: Dove Medical Press |
| References | Epstein (ref32) 2019; 7 Croote (ref40) 2018; 362 Gandhi (ref12) 2017; 13 Wambre (ref14) 2017; 9 Seidman (ref1) 2015; 152 Pavon-Romero (ref9) 2021; 182 Blauvelt (ref18) 2017; 389 Scadding (ref28) 2017; 317 Kucuksezer (ref3) 2020; 69 Nettis (ref43) 2020; 75 Winther (ref30) 2006; 36 Cox (ref26) 2011; 127 Amin (ref8) 2006; 117 Cox (ref27) 2010; 125 Chaker (ref31) 2016; 137 Swain (ref13) 1990; 145 Lebman (ref15) 1988; 168 Shamji (ref36) 2012; 67 Copenhaver (ref29) 2011; 107 Gleich (ref35) 1982; 70 Simpson (ref17) 2016; 375 Vignola (ref38) 2004; 59 Sturm (ref4) 2018; 73 Busse (ref25) 2020; 125 Paller (ref20) 2020; 83 Jiang (ref10) 2019; 40 Le Floc’h (ref16) 2020; 75 Penagos (ref7) 2018; 5 Paller (ref21) 2021; 35 Nolte (ref34) 2017; 5 Durham (ref6) 1999; 341 Jeannin (ref41) 1998; 160 Orban (ref44) 2021; 51 Castro (ref22) 2018; 378 Jonstam (ref37) 2019; 74 Weinstein (ref24) 2018; 142 Dhami (ref5) 2017; 72 de Bruin-Weller (ref19) 2018; 178 Sánchez-Borges (ref33) 2020; 40 Bachert (ref23) 2019; 394 Cavaliere (ref39) 2020; 227 Epstein (ref11) 2014; 2 Durham (ref2) 2016; 137 Bryant (ref42) 2007; 179 |
| References_xml | – volume: 83 start-page: 1282 year: 2020 ident: ref20 publication-title: J Am Acad Dermatol doi: 10.1016/j.jaad.2020.06.054 – volume: 142 year: 2018 ident: ref24 publication-title: J Allergy Clin Immunol doi: 10.1016/j.jaci.2017.11.051 – volume: 40 start-page: 25 year: 2020 ident: ref33 publication-title: Immunol Allergy Clin North Am doi: 10.1016/j.iac.2019.09.001 – volume: 9 start-page: eaam9171 year: 2017 ident: ref14 publication-title: Sci Transl Med doi: 10.1126/scitranslmed.aam9171 – volume: 5 start-page: 84 year: 2017 ident: ref34 publication-title: J Allergy Clin Immunol Pract doi: 10.1016/j.jaip.2016.08.017 – volume: 51 start-page: 329 year: 2021 ident: ref44 publication-title: Clin Exp Allergy doi: 10.1111/cea.13775 – volume: 13 start-page: 425 year: 2017 ident: ref12 publication-title: Expert Rev Clin Immunol doi: 10.1080/1744666X.2017.1298443 – volume: 107 start-page: 441 year: 2011 ident: ref29 publication-title: Ann Allergy Asthma Immunol doi: 10.1016/j.anai.2011.06.026 – volume: 178 start-page: 1083 year: 2018 ident: ref19 publication-title: Br J Dermatol doi: 10.1111/bjd.16156 – volume: 125 year: 2010 ident: ref27 publication-title: J Allergy Clin Immunol doi: 10.1016/j.jaci.2009.10.060 – volume: 75 start-page: 2653 year: 2020 ident: ref43 publication-title: Allergy doi: 10.1111/all.14338 – volume: 5 start-page: 275 year: 2018 ident: ref7 publication-title: Curr Treat Options Allergy doi: 10.1007/s40521-018-0176-2 – volume: 137 start-page: 452 year: 2016 ident: ref31 publication-title: J Allergy Clin Immunol doi: 10.1016/j.jaci.2015.08.046 – volume: 362 start-page: 1306 year: 2018 ident: ref40 publication-title: Science doi: 10.1126/science.aau2599 – volume: 394 start-page: 1638 year: 2019 ident: ref23 publication-title: Lancet doi: 10.1016/S0140-6736(19)31881-1 – volume: 72 start-page: 1825 year: 2017 ident: ref5 publication-title: Allergy doi: 10.1111/all.13208 – volume: 7 start-page: 1996 year: 2019 ident: ref32 publication-title: J Allergy Clin Immunol Pract doi: 10.1016/j.jaip.2019.01.058 – volume: 40 start-page: 102269 year: 2019 ident: ref10 publication-title: Am J Otolaryngol doi: 10.1016/j.amjoto.2019.07.013 – volume: 75 start-page: 1188 year: 2020 ident: ref16 publication-title: Allergy doi: 10.1111/all.14151 – volume: 341 start-page: 468 year: 1999 ident: ref6 publication-title: N Engl J Med doi: 10.1056/NEJM199908123410702 – volume: 36 start-page: 254 year: 2006 ident: ref30 publication-title: Clin Exp Allergy doi: 10.1111/j.1365-2222.2006.02340 – volume: 179 start-page: 8180 year: 2007 ident: ref42 publication-title: J Immunol doi: 10.4049/jimmunol.179.12.8180 – volume: 145 start-page: 3796 year: 1990 ident: ref13 publication-title: J Immunol doi: 10.4049/jimmunol.145.11.3796 – volume: 317 start-page: 615 year: 2017 ident: ref28 publication-title: JAMA doi: 10.1001/jama.2016.21040 – volume: 117 start-page: 169 year: 2006 ident: ref8 publication-title: J Allergy Clin Immunol doi: 10.1016/j.jaci.2005.10.010 – volume: 125 year: 2020 ident: ref25 publication-title: Ann Allergy Asthma Immunol doi: 10.1016/j.anai.2020.05.026 – volume: 127 start-page: S1 year: 2011 ident: ref26 publication-title: J Allergy Clin Immunol doi: 10.1016/j.jaci.2010.09.034 – volume: 389 start-page: 2287 year: 2017 ident: ref18 publication-title: Lancet doi: 10.1016/S0140-6736(17)31191-1 – volume: 137 start-page: 339 year: 2016 ident: ref2 publication-title: J Allergy Clin Immunol doi: 10.1016/j.jaci.2015.12.1298 – volume: 182 start-page: 553 year: 2021 ident: ref9 publication-title: Int Arch Allergy Immunol doi: 10.1159/000513158 – volume: 70 start-page: 261 year: 1982 ident: ref35 publication-title: J Allergy Clin Immunol doi: 10.1016/0091-6749(82)90062-8 – volume: 375 start-page: 2335 year: 2016 ident: ref17 publication-title: N Engl J Med doi: 10.1056/NEJMoa1610020 – volume: 35 start-page: 464 year: 2021 ident: ref21 publication-title: J Eur Acad Dermatol Venereol doi: 10.1111/jdv.16928 – volume: 74 start-page: 743 year: 2019 ident: ref37 publication-title: Allergy doi: 10.1111/all.13685 – volume: 2 start-page: 161 year: 2014 ident: ref11 publication-title: J Allergy Clin Immunol Pract doi: 10.1016/j.jaip.2014.01.004 – volume: 73 start-page: 744 year: 2018 ident: ref4 publication-title: Allergy doi: 10.1111/all.13262 – volume: 168 start-page: 853 year: 1988 ident: ref15 publication-title: J Exp Med doi: 10.1084/jem.168.3.853 – volume: 67 start-page: 217 year: 2012 ident: ref36 publication-title: Allergy doi: 10.1111/j.1398-9995.2011.02745.x – volume: 152 start-page: S1 year: 2015 ident: ref1 publication-title: Otolaryngol Head Neck Surg doi: 10.1177/0194599814561600 – volume: 69 start-page: 549 year: 2020 ident: ref3 publication-title: Allergol Int doi: 10.1016/j.alit.2020.08.002 – volume: 59 start-page: 709 year: 2004 ident: ref38 publication-title: Allergy doi: 10.1111/j.1398-9995.2004.00550.x – volume: 227 start-page: 81 year: 2020 ident: ref39 publication-title: Immunol Lett doi: 10.1016/j.imlet.2020.08.002 – volume: 160 start-page: 3555 year: 1998 ident: ref41 publication-title: J Immunol doi: 10.4049/jimmunol.160.7.3555 – volume: 378 start-page: 2486 year: 2018 ident: ref22 publication-title: N Engl J Med doi: 10.1056/NEJMoa1804092 |
| SSID | ssj0000396636 |
| Score | 2.404445 |
| Snippet | Subcutaneous immunotherapy (SCIT) has been proven as an effective therapy against some allergens for seasonal allergic rhinitis (SAR) patients unresponsive to... Background: Subcutaneous immunotherapy (SCIT) has been proven as an effective therapy against some allergens for seasonal allergic rhinitis (SAR) patients... Clinical Study Number: NCT03558997 Jonathan Corren,1 Sarbjit S Saini,2 Remi Gagnon,3 Mark H Moss,4 Gordon Sussman,5 Joshua Jacobs,6 Elizabeth Laws,7 Elinore S Chung,8 Tatiana Constant,8 Yiping... |
| SourceID | doaj pubmedcentral proquest gale pubmed crossref |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source |
| StartPage | 1045 |
| SubjectTerms | Allergens Allergic rhinitis Allergies Antihistamines Asthma Clinical outcomes Clinical trials Corticosteroids Dosage Drug dosages Drug therapy dupilumab Epinephrine Hay fever Histamine Immunotherapy Interleukin 13 Interleukin 4 Interleukins International organizations Monoclonal antibodies nasal allergen responses Original Research Patients Pharmaceutical industry Pharmacists Placebos Respiratory agents Rhinitis seasonal allergic rhinitis Sinusitis Steroids subcutaneous immunotherapy |
| SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3da9UwFA-yB_FFnJ_VqREGglC3Js1HfasfYw7mw3aHewtJk3gL196x3cuYf73ntFm5RcEXX5sTaM9Xfqc5H4TsRtZoiNF8Drazn5ci6NyySuSR-6hcwYLXWOB8_E0enpVH5-J8Y9QX5oQN7YEHxu1ZgCBWiVIFCWC2iVqGUnDlnJIem-Oh94VjbCOY6n0wBxjfzwcsCgiTZCXFUJyHY3n2jur6_Skos67Y5Djqu_b_6Zs3Dqdp4uTGSXTwgNxPEJLWw6tvkzuhe0juHqdL8kfk-nQOmDqfgc-l4BeaNeC_AAE-rbHs78cN_Yo1Iany6obaztPP64sWvJR11F4G-j0sFnS2XGC_5eBp26WdbUNP5i1mG119oDU9gZ3Ln-0vIJmhGj8mZwdfZp8O8zRfIW-E4qu8kFGALFwVKrdvARgq6wvpQgzKV1aUwGsRohdccOY0C4FJK4CvXuqomC74E7LVLbvwjFDmtS4s4zFggOak004LX_hGWO3Lkmfk3S2bTZOaj-MMjIWBIARlYkAmJskkI7sj8cXQc-PvZB9RXiMJNsruH4D6mKQ-5l_qk5HXKG0zVJ2O5m5qDKQg8NBlRt72FGjw8MqNTXUL8OHYOmtCuTOhBENtpsu3GmWSo7gygDgLhXfFsPxmXMadmPzWawfSQBCtwFlm5OmggONH8xIAhcTdaqKaE65MV7p23rcR11xVgC-f_w82viD3GCb79P-mdsjW6nIdXgJaW7lXvWH-Bp-OOt0 priority: 102 providerName: Directory of Open Access Journals – databaseName: ProQuest Central dbid: BENPR link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3_a9QwFA_zBuIv4nfrpkYYCELdNWmaVBDpdGMOdsjthvutJE26K5zt7XaHzL_e93q5uqL4a_MCTd6XfF7yvhCyV7JCgY9mQ9CdYRgLp0LNUhGW3JbSRMxZhQnOp6Pk-Dw-uRAXW2S0yYXBsMqNTWwNtW0KvCPfh6M5kvioFn-aX4XYNQpfVzctNLRvrWA_tiXG7pBthl2VB2T74HD0bdzdugw5wHt8r8REPWzRs3-SZe_PQLBVynpHU1vB_287feug6gdR3jqVjh6Q-x5O0mzN_4dky9WPyN1T_2D-mPw8mwK-DidgfynYiGIFWNCBs08zTAG8vKFfMT_EZ2HdUF1b-mU1r8BiaUP1wtHvbjajk2aGtZedpVXtZ1YFHU8rjDy6_kAzOoaZzY_qF5BMUKSfkPOjw8nn49D3WggLIfkyjJJSAF9M6lIz1AASpbZRYlzppE21iEuVCFdawQVnRjHnWKIF7KVNVCmZivhTMqib2j0nlFmlIs146dBZM4lRRgkb2UJoZeOYB-TdZpvzwhcix34YsxwcEuRJDjzJPU8CstcRz9f1N_5NdoD86kiwaHb7oVlc5l4Hcw1oVksRS5eAX1TAklwsuDRGJhbrLAbkNXI7X2egdqqfZ-hUgROi4oC8bSlQ-eGXC-1zGGDhWEarR7nbowSlLfrDG4nKvdG4zv-IeEDedMM4EwPhWulAGnCoJRjOgDxbC2C3aB4DuEhwtuyJZm9X-iN1NW1LiisuU8CaL_7_WzvkHsOQnvYGapcMlouVewmYbGleeUX7DdZNOAY priority: 102 providerName: ProQuest |
| Title | Short-Term Subcutaneous Allergy Immunotherapy and Dupilumab are Well Tolerated in Allergic Rhinitis: A Randomized Trial |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/34429614 https://www.proquest.com/docview/2561738914 https://www.proquest.com/docview/2564487319 https://pubmed.ncbi.nlm.nih.gov/PMC8379710 https://doaj.org/article/a192a7547e6049cf86e4537bb76d5060 |
| Volume | 14 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVAFT databaseName: Open Access Digital Library customDbUrl: eissn: 1178-6965 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0000396636 issn: 1178-6965 databaseCode: KQ8 dateStart: 20080101 isFulltext: true titleUrlDefault: http://grweb.coalliance.org/oadl/oadl.html providerName: Colorado Alliance of Research Libraries – providerCode: PRVAON databaseName: DOAJ Directory of Open Access Journals customDbUrl: eissn: 1178-6965 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0000396636 issn: 1178-6965 databaseCode: DOA dateStart: 20080101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals – providerCode: PRVBFR databaseName: Free Medical Journals customDbUrl: eissn: 1178-6965 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0000396636 issn: 1178-6965 databaseCode: DIK dateStart: 20080101 isFulltext: true titleUrlDefault: http://www.freemedicaljournals.com providerName: Flying Publisher – providerCode: PRVFQY databaseName: GFMER Free Medical Journals customDbUrl: eissn: 1178-6965 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0000396636 issn: 1178-6965 databaseCode: GX1 dateStart: 20080101 isFulltext: true titleUrlDefault: http://www.gfmer.ch/Medical_journals/Free_medical.php providerName: Geneva Foundation for Medical Education and Research – providerCode: PRVFQY databaseName: GFMER Free Medical Journals customDbUrl: eissn: 1178-6965 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0000396636 issn: 1178-6965 databaseCode: GX1 dateStart: 0 isFulltext: true titleUrlDefault: http://www.gfmer.ch/Medical_journals/Free_medical.php providerName: Geneva Foundation for Medical Education and Research – providerCode: PRVHPJ databaseName: ROAD: Directory of Open Access Scholarly Resources customDbUrl: eissn: 1178-6965 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0000396636 issn: 1178-6965 databaseCode: M~E dateStart: 20080101 isFulltext: true titleUrlDefault: https://road.issn.org providerName: ISSN International Centre – providerCode: PRVAQN databaseName: PubMed Central customDbUrl: eissn: 1178-6965 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0000396636 issn: 1178-6965 databaseCode: RPM dateStart: 20080101 isFulltext: true titleUrlDefault: https://www.ncbi.nlm.nih.gov/pmc/ providerName: National Library of Medicine – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: http://www.proquest.com/pqcentral?accountid=15518 eissn: 1178-6965 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0000396636 issn: 1178-6965 databaseCode: BENPR dateStart: 20080101 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVPQU databaseName: Public Health Database customDbUrl: eissn: 1178-6965 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0000396636 issn: 1178-6965 databaseCode: 8C1 dateStart: 20080101 isFulltext: true titleUrlDefault: https://search.proquest.com/publichealth providerName: ProQuest – providerCode: PRVFZP databaseName: Scholars Portal Journals: Open Access customDbUrl: eissn: 1178-6965 dateEnd: 20250131 omitProxy: true ssIdentifier: ssj0000396636 issn: 1178-6965 databaseCode: M48 dateStart: 20080901 isFulltext: true titleUrlDefault: http://journals.scholarsportal.info providerName: Scholars Portal – providerCode: PRVAWR databaseName: Taylor & Francis Open Access customDbUrl: eissn: 1178-6965 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0000396636 issn: 1178-6965 databaseCode: 0YH dateStart: 20081201 isFulltext: true titleUrlDefault: https://www.tandfonline.com providerName: Taylor & Francis |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3da9swEBddC6UvY-s-6q3LNCgMBu5iybLkwRhu15IVUkaasO7JSJbcGDynSxO27K_fneOEmuVpL36w7sDS_e50Z92dCDnKWaYgRrM-6E7XD4VTvmax8HNuc2kC5qzCAuf-ZdQbhRfX4nqLrC7jbBbwbmNoh_dJjabl8e-fi0-g8B8xjTkI5fuLJDm-AmyqGGzxDmxJDOHdb_z82iRz8OrxmHJ_A88e2eUhmOUoCFubU93D_19LfW-raqdR3tuXzh-Rh41DSZMlAh6TLVftk91-c2T-hPy6GsPk_CFYYApWIpuDN-gg3KcJFgHeLOgXrBBp6rAWVFeWfp7fFmCztKF66ug3V5Z0OCmx-7KztKgaziKjg3GBuUd3H2hCB8A5-VH8AZIhgvopGZ2fDU97fnPbgp8JyWd-EOUCJGNiF5uuBjdRahtExuVO2liLMFeRcLkVXHBmFHOORVrAstpI5ZKpgD8j29WkcgeEMqtUoBnPHYZrJjLKKGEDmwmtbBhyj7xbLXOaNa3I8UaMMoWQBMWTgnjSRjweOVoT3y47cGwmO0F5rUmwbXb9YjK9SRstTDX4s1qKULoIIqMMpuRCwaUxMrLYadEjr1Ha6bIGda38aYJhFYQhKvTI25oCAQmfnOmmigEmjo20WpSHLUpQ26w9vEJUukJ9Cv5nIPHkGIbfrIeRE1PhanQgDYTUEkynR54vAbie9ArHHpEtaLZWpT1SFeO6qbjiMgZv88V_c74kewzzferfU4dkezadu1fgsM1Mhzzofu_BU50GHbJzcnb5ddCpf350ajX9CyGjRPc |
| linkProvider | Scholars Portal |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtR3bbtMw1BpDgr0g7gQGM9IQElJY48Sxg4RQ2Jjabd3D1ml7C3bsrJG6pPSiqXwU38g5aRoWgXjba3wc2T53-1wI2c5YKsFHMy7wTscNuJWuYhF3M99kQnvMGokJzv3jsHsWHFzwizXya5ULg2GVK5lYCWpTpnhHvgOq2RP4qBZ8Gf9wsWsUvq6uWmgsyeLQLq7BZZt-7u0Bft8xtv9tsNt1664CbsqFP3O9MOOwAh3ZSHcUmENCGS_UNrPCRIoHmQy5zQz3uc-0ZNayUHFwCkwoM8Gk58N_75C7mGmEfCV3veZOp-MDHL6GYhogNgDaOYjjj6fANjJiLcVX9Qf4WwvcUIPtEM0bOm__IXlQG6s0XlLXI7Jmi8fkXr9-jn9Crk-HYL27A5DuFCRQOgdL05bzKY0xwfByQXuYfVLneC2oKgzdm49zkIdKUzWx9NyORnRQjrCyszU0L-qZeUpPhjnGNU0_0ZiewMzyKv8JIANkmKfk7FbO_BlZL8rCviCUGSk9xfzMoiuoQy215MYzKVfSBIHvkA-rY07Susw5dtsYJeDuIE4SwElS48Qh2w3weFnd499gXxFfDQiW5K4-lJPLpObwRIGtrAQPhA3B60phSzbgvtBahAarODpkC7GdLPNbG8GSxOiygYsjA4e8ryBQtMCSU1VnSMDGsUhXC3KzBQkiIW0PrygqqUXSNPnDQA552wzjTAyzq6gDYcBdFyCWHfJ8SYDNpv0ATJcQZ4sWabZOpT1S5MOqYLn0RQSW7Mv_L2uL3O8O-kfJUe_48BXZYBg8VN11bZL12WRuX4P1N9NvKpaj5Ptt8_hvoCxukg |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtR3bbtMw1BqdNPGCuFMYzEhDSEihjRPHDtKEOrpq3Vg1dZ22t2DHzlqppKUXTeMT-SrOSd2wCMTbXuPjyPa52-dCyG7GUgk-mvGAd5peyK30FIu5lwUmE9pn1khMcD7pRYfn4dElv9wgv9a5MBhWuZaJhaA2kxTvyBugmn2Bj2phI3NhEaftzufpDw87SOFL67qdhnJtFsxeUW7MJXkc25trcOfme9024P4dY52DwZdDz3Uc8FIugoXnRxmH1enYxrqpwFQSyviRtpkVJlY8zGTEbWZ4wAOmJbOWRYqDw2AimQkm_QD-e49sCswXrZHN_YPeab-88WkGAIlvpZgkiO2BGket1sczYCoZs4paLLoH_K0jbinJagDnLY3YeUgeOFOWtla094hs2Pwx2Tpxj_VPyPXZEGx7bwCyn4J8Spdgh9rJck5bmH54dUO7mJviMsBuqMoNbS-nI5CWSlM1s_TCjsd0MBlj3Wdr6Ch3M0cp7Q9HGPU0_0RbtA8zJ99HPwFkgOz0lJzfyak_I7V8ktsXhDIjpa9YkFl0FHWkpZbc-CblSpowDOrkw_qYk9QVQcdeHOMEnCHESQI4SRxO6mS3BJ6uan_8G2wf8VWCYMHu4sNkdpU4_k8UWNJK8FDYCHyyFLZkQx4IrUVksMZjnewgtpNV9mspdpIWOnTgAMmwTt4XECh4YMmpcvkTsHEs4VWB3K5AgsBIq8NrikqcwJonf9irTt6WwzgTg_AK6kAYcOYFCO06eb4iwHLTQQiGTYSzRYU0K6dSHclHw6KcuQxEDHbuy_8va4dsAb8nX7u941fkPsPIouIibJvUFrOlfQ2m4UK_cTxHybe7ZvPf4-N5oQ |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Short-Term+Subcutaneous+Allergy+Immunotherapy+and+Dupilumab+are+Well+Tolerated+in+Allergic+Rhinitis%3A+A+Randomized+Trial&rft.jtitle=Journal+of+asthma+and+allergy&rft.au=Corren%2C+Jonathan&rft.au=Saini%2C+Sarbjit+S&rft.au=Gagnon%2C+Remi&rft.au=Moss%2C+Mark+H&rft.date=2021-01-01&rft.pub=Dove&rft.eissn=1178-6965&rft.volume=14&rft.spage=1045&rft.epage=1063&rft_id=info:doi/10.2147%2FJAA.S318892&rft_id=info%3Apmid%2F34429614&rft.externalDocID=PMC8379710 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1178-6965&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1178-6965&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1178-6965&client=summon |